Patent ID: 9737617
Date: 2017-08-22
CPC Classifications: A61K,A61P,C07K

Claim:
1. A method of treating a B-cell lymphoma or leukemia, comprising administering to a subject with a B-cell lymphoma or leukemia a hexavalent DNL complex comprising: a. a first fusion protein comprising an AD (anchor domain) moiety from the N-terminus of an AKAP protein attached to the C-terminal end of an IgG antibody; and b. four copies of a second fusion protein comprising a DDD (dimerization and docking domain) moiety, wherein the amino acid sequence of the DDD moiety is selected from the group consisting of residues 1-44 of human protein kinase A (PKA) RIIα and residues 1-44 of human PKA RIIβ, attached to the C-terminal end of an antigen-binding antibody fragment; wherein pairs of the DDD sequence form dimers that bind to the AD moiety to form the DNL complex; and wherein the complex binds to human CD20 and human CD22.